HEAD-TO-HEAD COMPARISON
Compound Tirzepatide vs ZepboundTirzepatide vs Tirzepatide
Verdict: Same active molecule (tirzepatide). Zepbound is an FDA-approved finished drug product with consistent quality control. Compound Tirzepatide is a compounded preparation; price is historically much lower, but 503A compounding has been restricted since the FDA declared the shortage resolved. Verify the compounding pharmacy's Certificate of Analysis if pursuing the compound route.
Side-by-side comparison
| Compound Tirzepatide | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | 503A / 503B pharmacies | Eli Lilly |
| FDA approval | Not approved as finished product | 2023 |
| Indication | Not an FDA-approved finished product. 503A compounding is restricted now that the FDA has declared the tirzepatide shortage resolved. | Chronic weight management for adults with BMI 30+, or 27+ with at least one weight-related comorbidity |
| Starting dose | Step 1 of 6 | Step 1 of 6 |
| Maintenance target | 15 mg/week | 15 mg/week |
| Titration length | ~21 weeks | ~21 weeks |
| Mean weight loss | Same molecule as Mounjaro/Zepbound; outcomes track brand when correctly compounded | ~20.9% mean at 72 weeks (SURMOUNT-1) |
| HbA1c reduction | Same as branded tirzepatide | ~2.2 pp (off-label in T2D) |
| Cost (US list) | Historically $250 to $500 / mo during shortage | ~$1,060 / mo US list |
| Insurance | Not covered | Patchy for obesity indication |
Who should pick which
- Pick Zepbound if the primary goal is weight management with an obesity-indicated label. Higher maintenance dose and stronger trial weight-loss data.
- Consider Compound Tirzepatide only with a clinician's prescription and a verified Certificate of Analysis from the supplying pharmacy. Cost is meaningfully lower than Zepbound but supply has narrowed since FDA shortage resolution.
- Consider Compound Tirzepatide (tirzepatide) if mean weight loss in published trials is the deciding factor. Dual GIP + GLP-1 mechanism produces the largest effect size in head-to-head data.
Switching between the two
Because Compound Tirzepatide and Zepbound share the same active molecule, transitioning between them is straightforward: align the new product's dose to your existing maintenance level, or step into it at the closest available pen strength. No washout is typically needed.
Open Tirzepatide Dose Calculator → Compare full titration schedules side by sideFrequently asked
Is Compound Tirzepatide better than Zepbound?
Same active molecule (tirzepatide). Zepbound is an FDA-approved finished drug product with consistent quality control. Compound Tirzepatide is a compounded preparation; price is historically much lower, but 503A compounding has been restricted since the FDA declared the shortage resolved. Verify the compounding pharmacy's Certificate of Analysis if pursuing the compound route.
Can I switch from Compound Tirzepatide to Zepbound?
Because Compound Tirzepatide and Zepbound share the same active molecule, transitioning between them is straightforward: align the new product's dose to your existing maintenance level, or step into it at the closest available pen strength. No washout is typically needed.
Does Compound Tirzepatide produce more weight loss than Zepbound?
Compound Tirzepatide: Same molecule as Mounjaro/Zepbound; outcomes track brand when correctly compounded. Zepbound: ~20.9% mean at 72 weeks (SURMOUNT-1). Direct comparisons depend on dose, duration, and population studied; check the linked trial citations on each brand page for full context.
Why is Compound Tirzepatide priced differently from Zepbound?
Compound Tirzepatide costs Historically $250 to $500 / mo during shortage; Zepbound costs ~$1,060 / mo US list. Differences reflect manufacturer pricing strategy, FDA indication (obesity-labeled brands often face patchier insurance coverage than diabetes-labeled brands), and whether the product is a finished drug or a pharmacy compound.
Which is better for Type 2 diabetes, Compound Tirzepatide or Zepbound?
Both Compound Tirzepatide and Zepbound address T2D-relevant pathways via GLP-1 receptor activity. Trial HbA1c reductions: Compound Tirzepatide Same as branded tirzepatide; Zepbound ~2.2 pp (off-label in T2D).
Related
For research informational use only. Not medical advice. Zepbound is a registered trademark of its manufacturer. Consult a qualified healthcare provider for clinical decisions.